Health Catalyst Sees Q3 2024 Revenue $74.5M-$77.5M Vs $75M Estimate; Sees FY24 Revenue $304M-$312M Vs $307.7M Estimate
Portfolio Pulse from Benzinga Newsdesk
Health Catalyst (HCAT) has provided its revenue guidance for Q3 2024 and FY 2024. The company expects Q3 2024 revenue to be between $74.5 million and $77.5 million, compared to the $75 million estimate. For FY 2024, it anticipates revenue between $304 million and $312 million, versus the $307.7 million estimate.
August 07, 2024 | 9:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Health Catalyst (HCAT) has issued its revenue guidance for Q3 2024 and FY 2024. The company expects Q3 2024 revenue to be between $74.5 million and $77.5 million, compared to the $75 million estimate. For FY 2024, it anticipates revenue between $304 million and $312 million, versus the $307.7 million estimate.
The revenue guidance for both Q3 2024 and FY 2024 is slightly above the estimates, which is likely to be viewed positively by investors. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100